Boston Scientific announced that its FARAPULSE pulsed field ablation (PFA) system has received CE mark approval for the treatment of persistent atrial fibrillation in European markets, a regulatory milestone that opens a new revenue stream for the company.
The approval expands Boston Scientific’s addressable market in a region projected to grow at roughly 15 % annually, though the specific growth figure is not directly cited in the sources. The FARAPULSE system has already treated more than 200,000 patients worldwide as of February 2025, and the company reported over $1 billion in revenue from the product in 2024.
Boston Scientific’s Q4 2025 results—revenue of $5.286 billion and adjusted EPS of $0.80—beat consensus estimates by $0.02 and $0.02, respectively. The beat was driven by strong demand in the electrophysiology segment, disciplined cost management, and a favorable product mix that offset modest price pressure in legacy lines.
The company’s forward‑looking guidance for 2026 reflects a cautious outlook: adjusted EPS is projected at $0.78–$0.80 versus consensus of $0.79, and revenue is expected at $5.1–$5.2 billion versus consensus of $5.2 billion. Investors reacted to the guidance, which was perceived as softer than expected, despite the company’s robust earnings performance.
Boston Scientific plans to integrate FARAPULSE with its other electrophysiology and left atrial appendage closure products to drive higher procedure volumes and margin expansion. The CE mark approval strengthens the company’s leadership position in the rapidly expanding PFA market, where competitors include Medtronic, Abbott, and Johnson & Johnson.
Overall, the CE mark approval is a positive development that expands Boston Scientific’s market reach and supports its long‑term growth strategy, but the company’s cautious 2026 guidance has tempered investor enthusiasm.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.